|
業務類別
|
Biotechnology |
|
業務概覽
|
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it isobserved that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others. |
| 公司地址
| 321 Harrison Avenue, 8th Floor, Boston, MA, USA, 02118 |
| 電話號碼
| +1 781 797-0979 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.pepgen.com |
| 員工數量
| 81 |
| Ms. Mary Beth DeLena, J.D. |
General Counsel and Secretary |
-- |
25/04/2025 |
| Mr. Noel Donnelly, M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
美元 468.36K |
04/03/2026 |
| Dr. Paul D. Streck |
Executive Vice President, Head of Research and Development |
-- |
25/04/2025 |
| Mr. James McArthur, PhD |
President, Chief Executive Officer and Director |
美元 594.88K |
04/03/2026 |
|
|
| Ms. Laurie B. Keating, J.D. |
Chairman of the Board |
04/03/2026 |
| Dr. Joshua Resnick, M.B.A.,M.D. |
Director |
04/03/2026 |
| Ms. Lisa Wyman |
Director |
04/03/2026 |
| Mr. James McArthur, PhD |
President, Chief Executive Officer and Director |
04/03/2026 |
| Mr. Habib Joseph Dable |
Independent Director |
04/03/2026 |
| Dr. Howard Mayer, M.D. |
Independent Director |
04/03/2026 |
| Dr. Mitchell H. Finer, PhD |
Director |
04/03/2026 |
| Ms. Heidi Henson, C.P.A. |
Independent Director |
04/03/2026 |
|
|
|
|
